Skip to main content

March 2015, Vol 8, Sixth Annual Payers' Guide

FDA Approvals, Payers' Guide

The Sixth Annual Payers’ Guide to New FDA Approvals

Introduction, Payers' Guide

New FDA Drug Approvals Hit an 18-Year High in 2014

Gary M. Owens, MD

Payers' Guide, FDA Approvals

FDA Approvals of Brand-Name Prescription Drugs in 2014

Payers' Guide, FDA Approvals

Afrezza (Insulin Human) Inhalation Powder Approved for the Treatment of Patients with Type 1 or Type 2 Diabetes

Payers' Guide, FDA Approvals

Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non–Small-Cell Lung Cancer

Payers' Guide, FDA Approvals

Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Imbruvica (Ibrutinib), First-in-Class Bruton’s Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Invokamet (Canagliflozin plus Metformin HCl): First Fixed-Dose Combination with an SGLT2 Inhibitor Approved for the Treatment of Patients with Type 2 Diabetes

Payers' Guide, FDA Approvals

Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera

Lisa A. Raedler, PhD, RPh

Page 1 of 3
Results 1 - 10 of 27